Abstract

Success in treating diabetes is highly dependent on the patient's satisfaction with the therapy. The aim of the study was to assess the effectiveness and satisfaction of the use of Automatic Injection System GensuPen2 device which is a pen with a spring-assisted insulin release mechanism and a laterally located trigger. 4707 adult insulin treated diabetic patients (50.44% women) from all over Poland took part in the study. For 42% of subjects, the previously used pen was changed to the GensuPen2. During the first visit demographic and medical data were gathered. HbA1c was measured and the questionnaires concerning the satisfaction with the currently used pen and evaluation of pain severity, satisfaction with the treatment (all three are 5-point scales), and the health-related quality of life (HRQoL) were filled out twice - at the beginning and after 12 weeks of the study. The mean age was 64.8±10.1 years and duration of diabetes was 9.9±6.5 years. Impaired visual function was found in 13.7% and 12.3% of the subjects had an impaired manual efficiency. After 12 weeks, HbA1c level dropped from 8.26±1.17% to 7.72±0.89% (P <0.001). Satisfaction with the use of pen increased from on average 3.33 to 4.31 points (P <0.001) after switching to GensuPen2. Evaluation of pain severity revealed that discomfort and pain related to insulin injection decreased from on average 3.82 to 2.41 points (P <0.001). Insulin therapy with the use of GensuPen2 was comfortable for 94.48% of patients. More than half of the patients were more satisfied with GensuPen2 than with the previously used pen, and 98.63% of subjects declared that they did not want to return to previous pen. Satisfaction with diabetes treatment raised from 81.2% to 94.5% (P <0.001). The HRQoL increased from on average 5.81 to 7.39 points (P <0.001). The use of the GensuPen2 by diabetes patients improved metabolic control, increased satisfaction with diabetes treatment and the use of insulin pen, reduced the pain during injection, and improved their quality of life. Disclosure K. Cypryk: Advisory Panel; Self; Eli Lilly and Company, Novo Nordisk A/S. Speaker's Bureau; Self; Abbott, Servier. M. Zurawska-Klis: Speaker's Bureau; Self; Polfa Tarchomin S.A. Other Relationship; Self; Berlin-Chemie AG, Lilly Diabetes, Novo Nordisk Inc. Funding Bioton

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.